Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights – NVO
04:40pm, Thursday, 14'th Aug 2025
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
It's Time To Be All-In On Novo Nordisk
10:50am, Thursday, 14'th Aug 2025
Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin pressures. GLP-1 therapies, especially Ozempi
3 Absurdly Cheap Stocks That Haven't Been Trading This Low in Years
10:15am, Thursday, 14'th Aug 2025
If you want a good, deep value stock to buy, you often need to take on some risk, or at least accept some short-term uncertainty. But that patience can pay off in the long run.
NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
08:45am, Thursday, 14'th Aug 2025
NEW YORK , Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class perio
Novo Nordisk launches weight-loss drug Wegovy in South Africa
06:12am, Thursday, 14'th Aug 2025
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the coun
Why Novo Nordisk Stock Topped the Market Today
05:23pm, Wednesday, 13'th Aug 2025
Novo Nordisk (NVO 2.23%) is quite the divisive stock among both investors and analysts these days. Although its high-profile obesity drug Wegovy has been a raging success, the company is being rocked
September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO
04:41pm, Wednesday, 13'th Aug 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2
A Cure For Novo Nordisk
01:34pm, Wednesday, 13'th Aug 2025
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Wednesday, 13'th Aug 2025
BENSALEM, Pa. , Aug. 13, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
11:51am, Wednesday, 13'th Aug 2025
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
Novo Nordisk: The Falling Knife That Keeps Giving
11:14am, Wednesday, 13'th Aug 2025
Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in ob
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such in
ATTENTION NYSE: NVO INVESTORS: Contact Berger Montague About a Novo Nordisk A/S Class Action Lawsuit
06:06pm, Tuesday, 12'th Aug 2025
PHILADELPHIA , Aug. 12, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global
